SHC Stock Analysis — Sotera Health Company
Sector: Healthcare
AI Verdict
SHC trades at a low price for explosive expected growth, but if the regulatory moat doesn't translate into real earnings, the stock could snap back to a much higher multiple and punish late buyers.
Competitive Moat
Sotera Health provides essential sterilization and lab testing services for medical device and pharmaceutical manufacturers, which are tightly regulated and mission-critical for product safety. Its moat comes from regulatory barriers and long-term customer contracts that make switching costly and risky for clients.
Summary
A projected 281.6% jump in earnings is driving SHC's sharp drop from a trailing P/E of 66.9x to a forward P/E of just 17.5x.
Where It Stands
SHC trades at 17.5x next year's earnings—well below the healthcare sector's 22x median—after posting 8.2% revenue growth and a trailing P/E of 66.9x.
Key Metrics
- Trailing P/E: 66.9x
- Forward P/E: 17.5x
- PEG Ratio: 0.24
- Earnings Growth: +2.8%
- Revenue Growth: +0.1%
- 52-Week High: $19.85
- 52-Week Low: $13.09
Analyst Consensus
12 Buy · 3 Hold · 0 Sell (15 analysts)
Bull Case
With analyst consensus calling for 281.6% forward EPS growth, SHC is cheap for the growth you're getting at 17.5x forward earnings.
Bear Case
If the forward P/E reverts even halfway back to the trailing 66.9x, buyers today could see the multiple double and the stock price fall sharply if growth disappoints.
Catalyst to Watch
Quarterly earnings beats or misses will determine if the 281.6% EPS growth materializes and justifies the current valuation reset.